Electroacupuncture versus solifenacin for women with urgency-predominant mixed urinary incontinence: a protocol for a three-armed non-inferiority randomized controlled trial

Yuanjie Sun, Yan Liu, Tongsheng Su, Jianhua Sun, Ying Wu, Zhishun Liu, Yuanjie Sun, Yan Liu, Tongsheng Su, Jianhua Sun, Ying Wu, Zhishun Liu

Abstract

Background: Among women suffering from urinary incontinence (UI), about one-third are diagnosed with mixed urinary incontinence (MUI), among which urgency-predominant MUI causes more shame and inconvenience to patients. The treatments for urgency-predominant MUI have limited guidelines and previous studies have indicated that electroacupuncture (EA) might be a safe and effective option. The present study aims to evaluate the effect of EA on women with urgency-predominant MUI.

Methods: The study is a multicentered, three-armed, non-inferiority randomized clinical trial. A total of 282 female patients with urgency-predominant MUI will be randomly divided into three groups, namely the EA group, sham electroacupuncture (SA) group, and solifenacin treatment group at a ratio of 1:1:1. Thirty-six sessions of acupuncture treatment over 12 weeks and solifenacin treatment over 36 weeks will be provided. The primary outcome will be the decrease of urgency urinary incontinence (UUI) episodes after 12-week treatment. Secondary outcomes will include changes in incontinence episodes, urinary frequency, urgency, severity of symptoms, and influence on quality of life, assessed using the International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and Overactive Bladder Questionnaire Short Form (OAB-q SF). All patients will be continuously followed up until week 36 and their allocations will be statistically analyzed.

Discussion: Though placebo of solifenacin is rather difficult to access and all patients in the trial cannot be fully blinded, the present study will serve as an introduction of three-armed, randomized, non-inferiority, and sham acupuncture-controlled clinical trials to the acupuncture field, in an attempt to compare the effects of EA and solifenacin for treating women with urgency-predominant MUI.

Trial registration: ClinicalTrials.gov: NCT03787654. Registered on 25 December, 2018.

Keywords: Acupuncture; Antimuscarinic drugs; Stress; Urge.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study Flowchart. *The dose of solifenacin can be increased to 10 mg per day and can be discontinued following a comprehensive consideration of the state of incontinence symptoms and the side effects

References

    1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26. doi: 10.1007/s00192-009-0976-9.
    1. Wood LN, Anger JT. Urinary incontinence in women. BMJ. 2014;349:g4531. doi: 10.1136/bmj.g4531.
    1. Aoki Y, Brown HW, Brubaker L, et al. Urinary incontinence in women [J] Nat Rev Dis Prime. 2017;3:17042. doi: 10.1038/nrdp.2017.42.
    1. F.C. Burkhard (Chair) JLHRB, F. Cruz GEL, A.K. Nambiar NT, Tubaro A. EAU Guideline on Urinary Incontinence 2018. Available at: .
    1. Coyne KS, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int. 2003;92(7):731–735. doi: 10.1046/j.1464-410X.2003.04463.x.
    1. Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol. 2012;61(1):88–95. doi: 10.1016/j.eururo.2011.07.049.
    1. Kulseng-Hanssen S, Husby H, Schiøtz HA. Follow-up of TVT operations in 1113 women with mixed urinary incontinence at 7 and 38 months. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(3):391–396. doi: 10.1007/s00192-007-0449-y.
    1. Kelleher C, Cardozo L, Kobashi K, Lucente V. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(4):382–388. doi: 10.1007/s00192-005-0023-4.
    1. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health. 2005;8(4):495–505. doi: 10.1111/j.1524-4733.2005.00041.x.
    1. Liu B, Liu Y, Qin Z, et al. Electroacupuncture Versus Pelvic Floor Muscle Training Plus Solifenacin for Women With Mixed Urinary Incontinence: A Randomized Noninferiority Trial. Mayo Clin Proc. 2019;94:54–65. doi: 10.1016/j.mayocp.2018.07.021.
    1. F.C. Burkhard JLHRB, F. Cruz GEL, A.K. Nambiar NT, A. Tubaro Guidelines Associates: D. Ambühl DAB, F. Farag RL, Schneider MP. EAU Guidelines on Urinary Incontinence in Adults. Available at: . Accessed 4 Nov, 2017.
    1. Diokno AC, Catipay JR, Steinert BW. Office assessment of patient outcome of pharmacologic therapy for urge incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2002;13(5):334–338. doi: 10.1007/s001920200073.
    1. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–222. doi: 10.1016/j.juro.2008.03.028.
    1. Cartwright R, Srikrishna S, Cardozo L, Robinson D. Validity and reliability of the patient’s perception of intensity of urgency scale in overactive bladder. BJU Int. 2011;107(10):1612–1617. doi: 10.1111/j.1464-410X.2010.09684.x.
    1. Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int. 2008;102(9):1120–1127. doi: 10.1111/j.1464-410X.2008.07939.x.
    1. Wein AJ. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. J Urol. 2005;173(3):908–909.
    1. Huang L, Zhang SW, Wu SL, Ma L, Deng XH. The Chinese version of ICIQ: a useful tool in clinical practice and research on urinary incontinence. Neurourol Urodyn. 2008;27(6):522–524. doi: 10.1002/nau.20546.
    1. Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn. 2015;34(3):255–263. doi: 10.1002/nau.22559.
    1. McKown S, Abraham L, Coyne K, Gawlicki M, Piault E, Vats V. Linguistic validation of the N-QOL (ICIQ), OAB-q (ICIQ), PPBC, OAB-S and ICIQ-MLUTSsex questionnaires in 16 languages. Int J Clin Pract. 2010;64(12):1643–1652. doi: 10.1111/j.1742-1241.2010.02489.x.
    1. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189(1):98–101. doi: 10.1067/mob.2003.379.
    1. Pigeot I, Schäfer J, Röhmel J, Hauschke D. Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. Stat Med. 2003;22(6):883–899. doi: 10.1002/sim.1450.
    1. Rothmann MD, Wiens BL, Chan ISF. Design and analysis of non-inferiority trials. Chapman and Hall/CRC; 2016.
    1. Huitfeldt B, Hummel J, European Federation of Statisticians in the Pharmaceutical Industry (EFSPI). The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians. PHARM STAT. 2011;10(5):414-9.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel